137 related articles for article (PubMed ID: 26976208)
1. Mesenchymal stem cells secretomes' affect multiple myeloma translation initiation.
Marcus H; Attar-Schneider O; Dabbah M; Zismanov V; Tartakover-Matalon S; Lishner M; Drucker L
Cell Signal; 2016 Jun; 28(6):620-30. PubMed ID: 26976208
[TBL] [Abstract][Full Text] [Related]
2. Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells' phenotype and translation initiation.
Dabbah M; Attar-Schneider O; Tartakover Matalon S; Shefler I; Jarchwsky Dolberg O; Lishner M; Drucker L
Carcinogenesis; 2017 Jul; 38(7):708-716. PubMed ID: 28838065
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma and bone marrow mesenchymal stem cells' crosstalk: Effect on translation initiation.
Attar-Schneider O; Zismanov V; Dabbah M; Tartakover-Matalon S; Drucker L; Lishner M
Mol Carcinog; 2016 Sep; 55(9):1343-54. PubMed ID: 26293751
[TBL] [Abstract][Full Text] [Related]
4. BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner.
Ibraheem A; Attar-Schneider O; Dabbah M; Dolberg Jarchowsky O; Tartakover Matalon S; Lishner M; Drucker L
Transl Res; 2019 May; 207():83-95. PubMed ID: 30738861
[TBL] [Abstract][Full Text] [Related]
5. Ribosomal proteins as distinct "passengers" of microvesicles: new semantics in myeloma and mesenchymal stem cells' communication.
Dabbah M; Lishner M; Jarchowsky-Dolberg O; Tartakover-Matalon S; Brin YS; Pasmanik-Chor M; Neumann A; Drucker L
Transl Res; 2021 Oct; 236():117-132. PubMed ID: 33887527
[TBL] [Abstract][Full Text] [Related]
6. Niche origin of mesenchymal stem cells derived microvesicles determines opposing effects on NSCLC: Primary versus metastatic.
Attar-Schneider O; Dabbah M; Drucker L; Gottfried M
Cell Signal; 2020 Jan; 65():109456. PubMed ID: 31672605
[TBL] [Abstract][Full Text] [Related]
7. Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation.
Attar-Schneider O; Zismanov V; Drucker L; Gottfried M
Tumour Biol; 2016 Apr; 37(4):4755-65. PubMed ID: 26515338
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles.
Dabbah M; Jarchowsky-Dolberg O; Attar-Schneider O; Tartakover Matalon S; Pasmanik-Chor M; Drucker L; Lishner M
Carcinogenesis; 2020 Mar; 41(1):100-110. PubMed ID: 31586190
[TBL] [Abstract][Full Text] [Related]
9. Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4GI.
Attar-Schneider O; Drucker L; Gottfried M
Lab Invest; 2016 Sep; 96(9):1004-15. PubMed ID: 27501049
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation.
Dabbah M; Attar-Schneider O; Zismanov V; Tartakover Matalon S; Lishner M; Drucker L
J Leukoc Biol; 2016 Oct; 100(4):761-770. PubMed ID: 27272311
[TBL] [Abstract][Full Text] [Related]
11. The effect of mesenchymal stem cells' secretome on lung cancer progression is contingent on their origin: primary or metastatic niche.
Attar-Schneider O; Drucker L; Gottfried M
Lab Invest; 2018 Dec; 98(12):1549-1561. PubMed ID: 30089856
[TBL] [Abstract][Full Text] [Related]
12. Targeting eIF4GI translation initiation factor affords an attractive therapeutic strategy in multiple myeloma.
Attar-Schneider O; Drucker L; Zismanov V; Tartakover-Matalon S; Lishner M
Cell Signal; 2014 Sep; 26(9):1878-87. PubMed ID: 24815186
[TBL] [Abstract][Full Text] [Related]
13. eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's proteome and signaling.
Attar-Schneider O; Pasmanik-Chor M; Tartakover-Matalon S; Drucker L; Lishner M
Oncotarget; 2015 Feb; 6(6):4315-29. PubMed ID: 25717031
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E.
Zismanov V; Attar-Schneider O; Lishner M; Heffez Aizenfeld R; Tartakover Matalon S; Drucker L
Int J Oncol; 2015 Feb; 46(2):860-70. PubMed ID: 25422161
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells.
Attar-Schneider O; Drucker L; Zismanov V; Tartakover-Matalon S; Rashid G; Lishner M
Lab Invest; 2012 Feb; 92(2):178-90. PubMed ID: 22083671
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer effects of Staphylococcal Enterotoxin type B on U266 cells co-cultured with Mesenchymal Stem Cells.
Ejtehadifar M; Halabian R; Fooladi AAI; Ghazavi A; Mosayebi G
Microb Pathog; 2017 Dec; 113():438-444. PubMed ID: 29170042
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway.
Zhao P; Chen Y; Yue Z; Yuan Y; Wang X
Leuk Res; 2017 Jun; 57():20-26. PubMed ID: 28273548
[TBL] [Abstract][Full Text] [Related]
18. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
[TBL] [Abstract][Full Text] [Related]
19. Modulation of bone marrow mesenchymal stem cell secretome by ECM-like hydrogels.
Silva NA; Moreira J; Ribeiro-Samy S; Gomes ED; Tam RY; Shoichet MS; Reis RL; Sousa N; Salgado AJ
Biochimie; 2013 Dec; 95(12):2314-9. PubMed ID: 23994751
[TBL] [Abstract][Full Text] [Related]
20. Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells.
André T; Najar M; Stamatopoulos B; Pieters K; Pradier O; Bron D; Meuleman N; Lagneaux L
Cancer Immunol Immunother; 2015 Feb; 64(2):213-24. PubMed ID: 25341809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
